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Abstract
Cardiovascular disease (CVD) is the highest cause of death globally with more people dying annually from it than from
any other cause. CVD is associated with modifiable risk factors (dyslipidaemia, hypertension and diabetes) and treating
each of these factors lowers the risk of CVD. It is impossible to estimate the benefit of risk factor modification in the
individual patient and extrapolating data from multiple trials is difficult. It would be useful to have a marker of risk that
accurately estimates real time risk by measuring blood flow factors associated with the pathogenesis of atheroma. The
aim of this preliminary study was to validate a low-cost measurement technique for obtaining blood flow velocity profiles
and assess whether any of the measured and calculated factors, based on computational fluid dynamics (CFD) simulation,
known to be associated with atheroma was associated with coronary heart disease (CHD), thus establishing its feasibility
and acceptability as a clinical tool and suggesting areas for future research. Our study identified (i) that mean peak systo-
lic (PS) velocity being associated with CHD; individuals without CHD: mean (SD) = 62.8 (16.1) cm/s, with CHD: mean
(SD) = 53.6 (17.3) cm/s, p = 0.042; and (ii) that low-cost, portable ultrasound, which is routinely available in general prac-
tice, is a suitable assessment tool.
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Introduction
Cardiovascular disease (CVD) accounted for nearly a
quarter of deaths in the UK (152,465 of 597,206 deaths)
in 2016.1 Studies such as the Framingham Heart
Studies and Munster Heart Study have established that
CVD is associated with modifiable risk factors such as
hyperlipidaemia, hypertension, diabetes, smoking in
addition to age, male gender and a positive family his-
tory.2 Importantly many intervention studies treating
each of these modifiable risk factors have led to lower-
ing of CVD.3 These trials have formed the cornerstone
of an evidence-based approach to CVD prevention and
have resulted in various guidelines for each of the
above-mentioned risk factors; i.e. NICE guidelines,
Joint British Societies guidelines.4,5
Although this approach of treating risk factors
would be expected to result in benefit, it is impossible
to estimate benefit non-invasively whilst treating the
patient. Further, as clustering of risk factors is often
present many of the risk factors are simultaneously
addressed in the same patient.6,7 Evidence from rando-
mised controlled trials (RCT) seldom investigates inter-
action of parallel treatment effects, which is common in
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clinical practice. Thus, benefits observed in individual
RCTs may not accurately translate to such patients
encountered in a routine out-patient setting.
Ideally a near-patient estimation of a non-invasive
marker involved in the pathogenesis of CVD would be
useful to determine therapeutic effectiveness.8,9
Currently there is no routinely non-invasive method to
directly study cumulative risk reduction when multifa-
ceted risk reduction intervention is available in the
NHS in the UK. Such assessment would be useful in a
patient with diabetes where treatment is often tar-
geted at improving glycaemic control, dyslipidaemia,
hypertension, renal function etc. all of which have
effects on cardiovascular risk.7 A scheme of various
options assessing real time atherogenesis is presented
in Figure 1.
Vascular wall properties such as endothelial func-
tion, inflammation and smooth muscle proliferation
are considered important in the pathogenesis of athero-
sclerosis.8 Both, risk and protective factors of CVD
may influence the integrity of the endothelium.
Endothelial dysfunction is considered reversible by risk
factor modification.8–10 Thus, it is tempting to specu-
late that assessing the state of the endothelium could be
beneficial in assessing the risk of the individual.
Although it is the state of the coronary arteries that is
of paramount interest in the development of coronary
heart disease (CHD) it is seen that endothelial dysfunc-
tion represents a systemic disorder of the entire arterial
system. Figure 1 summarises the methods that could be
used to assess the state of the endothelium.
Vascular flow patterns can be affected by character-
istics of the arterial wall and result in such in endothe-
lial dysfunction.10 Thus, it is reasonable to assume that
studying suitable parameters of blood flow in the arter-
ial vasculature is possibly a method that could be uti-
lised to estimate cumulative cardiovascular risk.
Interestingly Halcox et al.11 demonstrated that coron-
ary endothelial dysfunction independently predicted
acute cardiovascular events. Conventional athero-
sclerosis risk factors such as diabetes, dyslipidaemia,
smoking and hypertension have been seen to alter
endothelial cell function.11,12
It has been seen that endothelial function has been
associated with vascular flow characteristics.13 The
pathogenesis of atherosclerosis is associated with both
vessel wall injury and other factors, both systemic and
local.13 It is suggested that atherosclerosis is related to
altered wall shear stress (WSS), particularly low WSS,
due to a decrease in nitric oxide synthase production,
vasodilation and cell repair.14–17 Malek et al.18 identi-
fied that WSS . 1.5Pa induces endothelial quiescence
and an atheroprotective gene expression profile, while
values \ 0.4 Pa were found at atherosclerosis-prone
sites resulting in stimulating an atherogenic phenotype.
Gijsen et al.19 classed WSS between 0 and 1Pa as ‘low’
while the range from 1 to 7Pa was being classed as ‘nor-
mal/high’ as in cultured endothelium the range from 1.2
Figure 1. A scheme of risk factors and the various options to assess real time atherogenesis together with possible mechanisms to
investigate the state of the endothelium is presented.
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to 1.5Pa was found to be most frequently atheroprotec-
tively associated though a plaque stenosis could see
values of 7 Pa and higher. A marker of overall vascular
risk could possibly be obtained from Computational
Fluid Dynamics (CFD) models derived from flow
characteristics obtained in turn from non-invasive tech-
niques. As the modelling is comprehensive (three-
dimensional and if necessary time-dependent) it is able
to provide complete predictive data for the derivation
of local wall shear stress. As explained by Cunningham
and Gotlieb20 the shear stress has a possible direct asso-
ciation with atherosclerosis: by studying its variation
and how it connects with the mechanism(s) of athero-
sclerosis it may provide estimates of both, risk estimate
and benefit in a real world setting. For routine use, a
non-invasive method as suggested by Chhabra9 is ideal
in an out-patient setting. An easily accessible blood ves-
sel with flow characteristics suitable for the resolution,
precision and accuracy of ultrasound (US) flow estima-
tion such as the carotid artery is potentially an ideal
start point. To explore the possibility of using US flow
parameters to study atherogenesis we embarked on a
study to derive a dataset necessary to enable computa-
tional risk flow data to be used clinically. We wished to
study these parameters in different patient groups inves-
tigating the association between the derived values and
estimated risk (comparison of patients with established
coronary heart disease (CHD) and individuals not
experiencing symptoms). In the event of an association
we hoped to design prospective studies to establish
whether any factors measured or derived by US could
predict real time atheroma. The aim of this paper was
to assess whether flow associated factors, measured or
derived from non-invasive carotid US was associated
with atheroma.
We would like to stress that whilst both, US Doppler
velocimetry and echo particle image velocimetry have been
applied in vitro and in vivo for similar applications, with
the benefit of being capable to provide flow data at higher
accuracy,21–24 this study was conducted purposefully on
routinely available portable US equipment to allow for
uptake as a possible routine diagnostics tool.
Materials and methods
Patients
Patients (ø18 years of age) with established CHD but
without known cerebrovascular disease (as carotid
atheroma could have potentially distorted measure-
ments) were identified from the Dyslipidaemia Clinics
at University Hospitals Birmingham NHS Foundation
Trust. All the above patients had an angiogram demon-
strating significant atheroma, hence they were referred
for secondary CVD prevention. None of the patients
had presented with symptoms/signs of cerebrovascular
disease. Sample size was determined a priori for a t-test
on the difference between two independent means (two
groups of equal size: mean WSS for healthy individuals
vs those with established CHD) using GPower.25 Mean
and standard deviation of WSS at peak systole is
expected to be 1.87 Pa and 0.41 Pa, respectively for
healthy subjects, and 1.53Pa and 0.40 Pa for subjects
with established CHD26; thus, the effect size calculated
by GPower is 0.84Pa, whereas the smallest change in
WSS detected was 0.34Pa. The above data suggested a
minimum sample of 26 subjects (Alpha=0.05 and
Power=0.90) in each arm. We fixed 4 days of recruit-
ment/US scanning having approached eligible patients
with CHD in previous clinics whilst controls (ø years
of age) were recruited from health service professionals
and patient relatives; this approach led to 27 patients
with established CHD and 30 individuals without symp-
toms suggestive of CHD to be included. Exclusion cri-
teria included individuals to provide written informed
consent, those with a history of prior carotid surgery,
carotid disease, superior vena cava obstruction or any
other event or procedure that would affect the vascular
anatomy, local blood flow or pressure (CG, a vascular
ultrasonographer had final responsibility for making
and documenting this decision) and cardiac arrhyth-
mias, individuals unable to tolerate lying semi-prone for
30min, haemoglobin \90 g/L or haematocrit \35,
broken or scarred skin overlying study site, previous
allergic reaction to aquagel (or topical creams, preserva-
tives in creams) and known pregnancy.
In the event of significant atheromatous plaque
being detected in those with CHD, the findings were
discussed in the clinic by SR, whilst in the case of volun-
teers (three individuals) the general practitioner was
informed of the findings via letter with advice on asses-
sing CVD risk factors, including lipoprotein(a), an
independent risk marker associated with CVD and
CVD risk lowering treatment. None of the scanned
patients withdrew from the study or suffered adverse
effects during the scanning process. There were no com-
plaints of inconvenience in attending the given appoint-
ment. No data could be obtained in one patient due to
interference in the cervical region (left and right). The
patient was informed of this and scanning was aborted.
Ethics committee approval was obtained from the
Health Research Authority (West Midlands – Solihull
Figure 2. A diagrammatic view of the data collection site.
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Research Ethics Committee; 15/WM/0164, IRAS proj-
ect ID 164622). The Heart of England NHS
Foundation Trust (now University Hospitals
Birmingham NHS Foundation Trust) acted as the
sponsor (Study Number: VascUsValidation2014) while
the study was conducted in accordance with the sub-
mitted protocols. As the study was primarily investigat-
ing methodology we were precluded from obtaining
demographic data from controls.
Ultrasound assessment
All US measurements were conducted in accordance with
the ‘Joint Recommendations for Reporting Carotid
Ultrasound Investigations in the United Kingdom’.27
The Mindray M9 US scanner was selected in view of
availability and portability, its specifications can be found
on the web.28 A Linear 14–4MHz transducer with a fre-
quency of 9MHz (with Harmonics on) was used with a
sample volume of 0.5mm. An angle of 60 was used
when measuring flow so that results were as accurate as
possible. The depth on screen (only accurate to 0.1 cm)
was used to check each image to ensure correct position-
ing when sampling in B mode (Acoustic Power was
96.6%, depth 4 cm, gain 28, frame rate 46, dynamic range
110, iClear 4, iBeam1). The scanning was carried out by a
vascular ultrasonographer working for both, Mindray
and the University of Birmingham NHS Foundation
Trust.
Due to easy accessibility the Common Carotid
Artery (CCA) was chosen as the site best suited for this
phase of the study. In view of anatomical variation of
the CCA and its bifurcation into the external carotid
artery (ECA) and internal carotid artery (ICA) it was
necessary to establish a standardised scanning protocol.
Figure 2 provides a diagrammatic illustration of the
data collection site.
US velocity data was collected in position 1 as seen
in Figure 2. Initially position 2 was identified, being
2.5 cm away from junction where the CCA bifurcates
into the ICA and ECA, thus ensuring that the outlet
boundary to be applied in the CFD model is sufficiently
far away from the junction (position 2) to cause any
negative impact on the accuracy of the computational
model. The inlet for the CFD model was taken to be
3 cm upstream (position 1). The scanning angle a, was
fixed to 60 for all measurements.
A number of pre-tests were conducted to establish
an appropriately resolved cross-sectional velocity pro-
file including varying the size of the interrogation win-
dow and the number of fixed increment steps. To
improve the resolution also an off-set scan repetition
was conducted as illustrated in Figure 3. Starting from
an initial 2mm interrogation window (pre-set), the
increment steps were repeatedly halved to optimise
the velocity profile resolution. The optimal scanning
increments were found to be 0.5mm in the central
region reducing to 0.2mm in the near-wall region.
The influence of the scanning direction was found to
be negligible.
CFD simulations
The mean peak systolic (PS) velocity profile was
extracted from the US scans to reconstruct the inlet
velocity profile for the CFD simulations (Figure 4(a)).
Due to the scanning resolution decreasing near the wall
the profile close to the wall was constructed by estimat-
ing the boundary layer thickness based on the
Womersley number which was calculated from the
heart rate. From the scan data it was estimated whether
a near wall measurement fell in the boundary region or
not. Depending on this estimate either two or three
points were added allowing to complete the profile to
the wall linearly (Figure 4(b)). Subsequently the data
was smoothed in order to obtain a representative pro-
file as the original raw data is affected by some noise
(red crosses in Figure 4(b)). This was anticipated to
allow reasonably accurate predictions of WSS even
close to the inlet boundary.
Figure 3. Repeat off-set scan test were conducted by translating the measurement points by half of the interrogation window size.
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The scale dimensions were obtained from the 2D US
scan images and shown in Figure 5(a). Using a free-
ware digitising software (WebPlotDigitizer) the wall
profile for each subject was extracted point wise using
a fine spatial discretisation and then processed with a
Matlab script to smooth, resample, rotate and cut to
generate a suitable, high quality 2D geometry to be
used in the CFD simulation which was performed using
Ansys Fluent. An example of this reconstruction is pre-
sented in Figure 5(b). It is also noteworthy that the
Matlab script identified the centre line of the individual
CCA segment.
The above described geometry manipulation allowed
for the application of horizontal inlet boundary condi-
tions as well as avoiding any possible interference from
the bifurcation beyond the outlet. The geometry was
meshed including a proper size bias in the vertical direc-
tion to enhance grid resolution. This was achieved by
ensuring approximately squared cells in the central
region of the domain and thinner cells in the near-wall
region, provided that a maximum cell aspect ratio was
respected. The example in Figure 6 demonstrates the
resulting grid distribution based on approximately 2000
mesh cells while the results were extracted from mesh
sizes of approximately 45,000 cells. Estimating the velo-
city, u, and the friction factor, f, a maximum y+ value
was also imposed along the wall. This was carried out,
despite the flow being in the laminar region to ensure
that a fine grid resolution at the wall was achieved
enabling obtainment of accurate WSS values. The result
of a conducted mesh independence test based on aver-
age cell size versus average WSS values obtained is
reported in Figure 7. The average cell size chosen for
the simulations is identified by the vertical black line in
the image. Zero cell size value is predicted using the
Richardson extrapolation method.29 The US
Figure 4. Velocity profile reconstruction: (a) sample US velocity readings and (b) sample velocity profile reconstruction (x-axis is
the normalized local coordinate across the diameter, y-axis is the velocity in the x direction).
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determined velocity profile was imposed as inlet bound-
ary condition, whereas wall BCs were set at the walls,
and a reference pressure was set at the outlet boundary.
The fluid flow was treated as 2D, laminar and steady
state. To model the non-Newtonian behaviour of blood
the Carreau model was applied for the blood viscosity.
Dynamic viscosity is modelled as dependent upon shear
rate, and independent from temperature as follows
m=m‘ + m0  m‘ð Þ 1+ _g2l2
 n1
2 ð1Þ
where m is the dynamic viscosity and _g the shear rate.
Infinite shear viscosity was set to m‘ =3.5e–3kg/ms,
zero shear viscosity to m0 =5.6e–2 kg/ms, relaxation
time to l=3.313 s and power law index n=0.3568
according to Siebert and Fodor.30 Blood density was
set to 1050 kg/m3. All flow variables were set to second
order of accuracy and the convergence level reached by
the simulations was such that the maximum residuals
were \ 1028. The CFD code used for the fluid flow
simulations was Ansys-Fluent.
The numerical model described above was validated
against analytical solutions for the laminar steady flow
of a Carreau fluid in 2D parallel-plates channel geome-
try from the literature.31 There the volumetric flow rate
_V is expressed as function of the channel geometry
(width W and height H), wall shear stress tw, and an








The integral in equation (1) is then analytically solved
and expressed in terms of sums of hypergeometric func-
tions involving the fluid rheological properties. For a






as from31 the wall shear stress can thus be analytically
derived as
Figure 5. Geometry identification: (a) scale determination and (b) geometric reconstruction and midline determination; the image
in (b) is a mirror image to (a).
Figure 6. Resulting mesh distribution indicatively
demonstrated for a mesh size of 2000 cells.
Figure 7. Mesh independence test shown for average WSS as a
function of mesh size (black line indicates the average cell size
used in this study).







For validation purposes a series of CFD analyses were
carried out for the steady laminar flow in a 2D parallel-
plates channel. The chosen channel had comparable
size to the simulated arteries (height H=6mm, length
L=3 cm) and was meshed following the same strategy.
The fluid properties were the same and a periodic
boundary condition was used for the inlet/outlet sec-
tions in order to model a fully-developed flow.
Simulations were run for different volumetric flow rates
(namely, 0.6, 6, 60, 600 and 3000 cm3/s) in order to
span shear rate values at the wall approximately in the
range [0.1, 500]. WWS values were then extracted from
the simulations and compared to the ones predicted
analytically. Results of the validation are shown in
Figure 8 where the maximum discrepancy between the
numerical and the analytical model is found to be
\ 0.5%.
Statistical analysis
The variables measured included mean peak systolic
(PS) velocity, velocity gradient and profiles and values
derived such as WSS assessed by US measurements at
Figure 8. Validation tests for Carreau fluid for laminar flow in
a 2D parallel-plates channel.
Figure 9. Typical results obtained from the CFD simulation: (a) iso-velocity-contours, (b) iso-pressure contours, and (c) WSS along
the walls. (i and ii) refer to a healthy and a CVD subject, respectively.
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peak systole in the common carotid artery (CCA) and
shown in Table 1. Initially t-tests were carried out to
establish if any of these measured/derived parameters
(independent variables) differed between individuals with
established CHD and those without CHD symptoms
(dependent variable). The number of patients and the pre-
liminary nature of this pilot study did not allow multiple
regression analysis where confounders could be adjusted
for. Factors that were significantly different between the
patient groups were further investigated (dependent vari-
ables) with linear regression (in the event of continuous
distribution) or logistic regression (in the event of a dichot-




Figure 9 shows typical results as obtained from two
exemplary CFD simulation cases (one healthy and one
CVD) such as iso-contours of velocity (Figure 9(a)) and
pressure (Figure 9(b)) as well as the corresponding wall
shear stress (WSS) distributions along the walls (Figure
9(c)). As would be anticipated for steady flow the flow dis-
tribution is strongly dependent on the imposed inlet velo-
city profile in the central, non-boundary regions of the
simulation domain. In areas where the CCA widens due to
the slightly irregular nature of the vessel wall the near wall
regions show an extended region of low velocity flow due
to the jet effect of the core flow. This results in different
velocity gradients along the wall causing significant varia-
tion of the WSS as can be seen in Figure 9(c). Following
the completion of all simulations, a thorough data analysis
was conducted which included skewness and kurtosis of
velocity profiles amongst other calculations of as well as
calculation of the percentage areas where the WSS was
found to be below certain threshold values (WSS \ 1,
WSS \ 2 andWSS \ 3Pa).
Comparison of measured and derived parameters:
Between group evaluation
Table 1 shows the measured and derived variables gath-
ered for each scanned individual using the methodology
described in the previous section. We looked for differ-
ences in US data and CFD outputs between two groups
of patients (with established CHD vs no evidence of
CHD) via unpaired t-tests (Table 2). Associations
between significant US factor(s) relating to the CFD
outputs (independent variables) and other measured/
derived factors (dependent variables) were determined
by linear regression analyses.
Table 2 shows that mean PS velocity was associated
with CHD; individuals without CHD: mean (SD)
=62.8 (16.1) cm/s, with CHD: mean (SD) =53.6
(17.3) cm/s, p=0.042. None of the other measured or
derived factors was statistically different between the 2
cohorts. Linear regression analyses in Table 3 showed
that PS velocity was associated with the following CFD
outputs: average pressure drop in the carotid bulb (p
\ 0.001), area of WSS in the location of the bulb less
than 1Pa (p=0.016), area of WSS in the location of
the bulb less than 2Pa (p=0.006), area of WSS in the
location of the bulb less than 3Pa (p=0.001) and area
of WSS upstream of the bulb less than 3Pa (p=0.017).
Discussion
The aim of the study was to evaluate the necessary
dataset enabling ultrasound based measured and
derived flow data to be used clinically. We then com-
pared these parameters in individuals with established
CHD and those not experiencing symptoms of CVD.
Our results in conjunction with other studies suggest
that PS velocity may be an area of interest. Even with a
small number of subjects a significant difference was
observed between the 27 patients with diagnosed CHD
and the 30 individuals without CVD symptoms. It was
also interesting that the PS velocity was associated with
many other factors that we measured/derived that were
of interest in atherogenesis.
Previous research has hinted that PS velocity, a
robust and easily obtainable non-invasive measure in
various vascular beds may be possibly a suitable identi-
fier associated with atherogenesis. Chuang et al.32
obtained baseline quantitative CCA US data from the
Cardiovascular Diseases Risk Factor Two-Township
Study in 3146 Taiwanese adults and studied ischaemic
heart disease (n=220) and strokes (n=247) after a
median follow-up of 12.8 years. PS velocity (\ 65 cm/s
vs ø 80 cm/s) was associated with CVD (Hazard ratio:
3.23, 95% confidence intervals: 2.51–4.15, p \ 0.0001).
It must be stated that end diastolic pressure (\ 15 cm/s
vs ø 20 cm/s) was even better at identifying CVD
(Hazard ratio: 4.54, 95% confidence intervals: 3.51–
5.85, p \ 0.0001). Chung et al.33 in the I-Lan
Longitudinal Aging Study found that low PS and end
diastolic velocities were associated with cognitive dys-
function as assessed by mini-Mental State Examination
and neuropsychological tests in 1684 Taiwanese sub-
jects without cognitive impairment at baseline. Zhang
et al.34 found in their patient study that carotid artery
plaque score (CAPS), combined with the PS velocity of
the right internal carotid artery has a greater predictive
value for CHD than CAPS alone.
Westholm et al.35 estimated the prognostic function
of PS velocity in the basal segments of the left ventricle
obtained from tissue Doppler imaging in 227 acute cor-
onary syndrome patients. They found that a composite
outcome of death, re-admission related to acute coron-
ary syndrome and heart failure was associated indepen-
dently with lower PS velocity. Further, it appeared that
PS velocity was more predictive of the monitored out-
come (estimated via area under the receiver operated
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Table 1. Measured and derived variables from the US scan on each individual.
Variable Derivation Unit Mean 6 SD
L-CCA lumen Measured from scan cm 0.67 6 0.11
Scan distance Measured from scan cm 2.13 6 0.33
Avg heart rate Measured from scan bpm 66.47 6 10.54
Max heart rate Measured from scan bpm 72.77 6 11.87
Min heart rate Measured from scan bpm 60.27 6 9.67
Max 6 Min heart rate ratio Derived from scan – 1.21 6 0.13
Heart rate Std Dev Derived from scan bpm 3.77 6 2.44
Avg Womersley number Derived from scan – 4.87 6 0.80
Expected boundary layer thickness Derived from scan mm 0.70 6 0.05
Average PS velocity Derived from scan cm/s 59.16 6 16.42
PS mass flow rate Derived from scan g/s 22.56 6 8.93
Avg PS Reynolds number Derived from scan – 1199.00 6 371.10
Avg velocity Derived from scan cm/s 0.49 6 0.02
Velocity std dev Derived from scan cm/s 0.25 6 0.01
Velocity profile skewness Derived from scan – 0.04 6 0.09
Velocity profile kurtosis Derived from scan – 1.94 6 0.06
L-CCA lumen CFD model mm 6.72 6 1.03
Inlet section length CFD model (bulb) mm 6.72 6 1.03
Outlet section length CFD model (bulb) mm 7.28 6 1.51
Upper wall length CFD model (bulb) mm 26.18 6 3.77
Lower wall length CFD model (bulb) mm 26.30 6 3.54
Avg dynamic viscosity at inlet section CFD model (bulb) cP 5.37 6 0.70
Avg dynamic viscosity at outlet section CFD model (bulb) cP 5.20 6 0.60
Avg dynamic viscosity at upper wall CFD model (bulb) cP 4.66 6 0.90
Avg dynamic viscosity at lower wall CFD model (bulb) cP 4.40 6 0.94
Avg static pressure at inlet section CFD model (bulb) Pa 55.43 6 122.39
Avg static pressure at outlet section CFD model (bulb) Pa -0.01 6 0.02
Relative Pressure drop CFD model (bulb) Pa/m 2214.92 6 5046.03
Avg total pressure at inlet section CFD model (bulb) Pa 352.98 6 211.77
Avg total pressure at outlet section CFD model (bulb) Pa 300.79 6 193.40
Relative total pressure drop CFD model (bulb) Pa/m 2055.91 6 1840.34
Avg WSS at upper wall CFD model (bulb) Pa 2.95 6 1.78
Avg WSS at lower wall CFD model (bulb) Pa 3.47 6 2.04
Inlet section length CFD model (upstream) mm 6.54 6 1.16
Outlet section length CFD model (upstream) mm 7.13 6 1.16
Upper wall length CFD model (upstream) mm 21.99 6 4.78
Lower wall length CFD model (upstream) mm 22.16 6 4.73
Avg dynamic viscosity at inlet section CFD model (upstream) cP 5.27 6 0.69
Avg dynamic viscosity at outlet section CFD model (upstream) cP 5.28 6 0.73
Avg dynamic viscosity at upper wall CFD model (upstream) cP 4.07 6 0.45
Avg dynamic viscosity at lower wall CFD model (upstream) cP 4.07 6 0.60
Avg static pressure at inlet section CFD model (upstream) Pa 7.74 6 57.82
Avg static pressure at outlet section CFD model (upstream) Pa 0.00 6 0.00
Relative Pressure drop CFD model (upstream) Pa/m 266.80 6 2775.70
Avg total pressure at inlet section CFD model (upstream) Pa 335.24 6 178.82
Avg total pressure at outlet section CFD model (upstream) Pa 286.64 6 156.16
Relative total pressure drop CFD model (upstream) Pa/m 2325.03 6 1641.38
Avg WSS at upper wall CFD model (upstream) Pa 3.39 6 2.21
Avg WSS at lower wall CFD model (upstream) Pa 3.16 6 1.13
Avg WSS CFD model (bulb) Pa 3.18 6 1.76
WSS variance CFD model (bulb) Pa2 7.55 6 13.82
WSS std dev CFD model (bulb) Pa 2.26 6 1.57
WSS 3rd order moment CFD model (bulb) Pa3 30.99 6 83.86
WSS skewness CFD model (bulb) – 0.75 6 0.53
WSS 4th order moment CFD model (bulb) Pa4 648.17 6 2369.66
WSS kurtosis CFD model (bulb) – 3.25 6 1.25
WSS area \ 1 Pa CFD model (bulb) % 26.17 6 17.93
WSS area \ 2 Pa CFD model (bulb) % 41.55 6 22.07
WSS area \ 3 Pa CFD model (bulb) % 57.98 6 24.31
Avg WSS CFD model (upstream) Pa 3.23 6 1.20
WSS variance CFD model (upstream) Pa2 4.61 6 7.89
WSS std dev CFD model (upstream) Pa 1.83 6 1.13
WSS 3rd order moment CFD model (upstream) Pa3 18.97 6 51.40
WSS skewness CFD model (upstream) – 0.91 6 0.76
(continued)
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curve) and less dependent on image quality than other
measures obtained from an echocardiography such as
ejection fraction, wall motion scoring and 2D strain.
Erectile dysfunction appears to be a powerful predic-
tor of CVD, CHD and all-cause mortality.36,37 Thus, it
is worth studying markers of atherogenesis in men
included within this high CVD risk clinical presentation
phenotype. Vicari et al.38 measured penile PS velocity
in 65 consecutive men suffering from erectile dysfunc-
tion and found that lower PS velocity was associated
with generalised atherosclerosis. Previously El-Sakka
and Morsy39 had suggested that CHD was associated
with penile lower PS velocity. They studied 303 men
with erectile dysfunction and found that 31.4% had
ischaemic heart disease which was associated with low
PS velocity (but not end diastolic velocity) in the caver-
nosal arteries. Further, greater severity of ischaemic
heart disease was related to lower PS velocity values
and they suggested penile US as a screening tool in men
with erectile dysfunction. Gupta et al.40 reviewed the
role of penile US as a predictor of CVD in view of tra-
ditional CVD risk factors such as diabetes, obesity, diet
and physical activity only identifying half of high risk
individuals. They carried out penile Doppler US in 49
men with erectile dysfunction prior to stress
echocardiography which showed abnormalities in 20%
of the men. PS velocity \ 30 cm/s was significantly
associated with abnormalities.
The association between PS velocity and atherogen-
esis must not be mistaken for causality. It is possible
that PS velocity is associated with many factors such as
for example endothelial dysfunction or arterial stiffness
that may contribute to atheroma formation and hence
may be a superior predictor than each of these factors
considered separately. It could be that PS velocity is a
surrogate for many factors, hence it possesses greater
predictive ability. It is possible that WSS may be one
such causative factor (although our data does not sug-
gest this –Table 2). Low WSS (WSS \ 1, \ 2 and
\ 3Pa) as expected was inversely correlated with PS
velocity in our analysis (Table 3). A prospective study
of the association between WSS and atherogenesis will
require a significantly larger cohort and include many
other confounders that may either be associated with
WSS and/or the pathogenesis of atheroma. Such analy-
ses may point to the exact role PS velocity plays in
atherogenesis, either a mediator or a surrogate marker.
The above data suggests a potential predictive role
for PS velocity in various vascular beds. However, it is
essential to standardise the data collection and collect
Table 1. Continued
Variable Derivation Unit Mean 6 SD
WSS 4th order moment CFD model (upstream) Pa4 272.24 6 1152.84
WSS kurtosis CFD model (upstream) – 4.09 6 2.05
WSS area \ 1 Pa CFD model (upstream) % 13.17 6 15.02
WSS area \ 2 Pa CFD model (upstream) % 31.93 6 23.81
WSS area \ 3 Pa CFD model (upstream) % 55.49 6 25.48
Min upstream artery diameter (Ø) Derived from scan cm 0.63 6 0.10
Max bulb artery Ø (without bifurcation) Derived from scan cm 0.86 6 0.17
Max bulb artery Ø (with bifurcation) Derived from scan cm 0.83 6 0.14
Max 6 Min artery Ø ratio (without bifurcation) Derived from scan – 1.38 6 0.26
Max 6 Min artery Ø ratio (with bifurcation) Derived from scan – 1.34 6 0.21
Table 2. Unpaired t-tests comparing volunteers (n = 30) with patients (coronary heart disease). Only velocity was significantly
different between the two groups.
Variable Controls (No CVD), n = 30 CHD, n = 27 p
mean (SD) mean (SD)
Avg PS velocity (cm/s) 62.8 (16.1) 53.6 (17.3) 0.042
Avg static pressure (upstream) drop (Pa/m) 2950.3 (6473.3) 1317 (2417.8) 0.22
Avg total pressure (upstream) drop (Pa/m) 2208.3 (1761.1) 1811.9 (1942.4) 0.42
CFD WSS distribution (bulb) avg Pa 3.5 (2.1) 5.0 (11.3) 0.46
CFD WSS distribution (bulb) std dev Pa 3.6 (2.0) 4.2 (11.8) 0.48
CFD WSS distribution (bulb) area \ 1 Pa 24.5 (18.3) 29.5 (18.9) 0.32
CFD WSS distribution (bulb) area \ 2 Pa 41.1 (21.2) 43.1 (23.6) 0.74
CFD WSS distribution (bulb) area \ 3 Pa 57.5 (23.2) 59.0 (25.6) 0.82
CFD WSS distribution (upstream) avg Pa 3.2 (1.3) 5.7 (13.3) 0.34
CFD WSS distribution (upstream) std dev Pa 2.1 (1.4) 4.3 (14.0) 0.39
CFD WSS distribution (upstream) area \ 1 Pa 15.2 (15.4) 13.3 (19.3) 0.69
CFD WSS distribution (upstream) area \ 2 Pa 32.2 (22.9) 33.5 (26.5) 0.84
CFD WSS distribution (upstream) area \ 3 Pa 55.6 (24.7) 56.4 (26.8) 0.91
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robust data with optimal precision and accuracy in dif-
fering patient groups (e.g. gender, height, weight/waist
circumference, ethnicity, diabetes/metabolic syndrome
and underlying risk factors), arteries varying in dia-
meter and equipment differing in resolution, practical-
ity etc. Our data and dataset obtained is strictly
applicable to the Mindray M9 portable US. It is essen-
tial that all US equipment manufacturers are aware of
the potential use of PS velocity as a screening tool and
carry out optimisation enabling accurate and precise
readings that could be clinically useful. Interestingly
Song et al.41 described a new wireless carotid neckband
Doppler system containing US sensors which measured
PS velocity comparable to a conventional US machine.
This system could potentially add to the type of studies
currently designed allowing flow measurements over a
longer period of time.
Study strengths and limitations
Although the cohort was small, the study has provided
some interesting findings. We used a portable ultra-
sound machine and replicated the association between
PS velocity and CHD, which will be useful for future
studies regarding convenience. Portable equipment
such as ours would allow a wider patient catchment in
future studies. Following validation of our findings, PS
velocity via portable US equipment could be used as an
identifier and possibly also as a predictor, not just in a
central location, but also potentially in primary care.
The fact that previously reported associations between
PS velocity and CHD in the carotid artery and other
vascular beds was confirmed in such a small patient
group using portable equipment with relatively low res-
olution suggests an important role for PS velocity as a
predictor of atherogenesis. However, the modest cohort
precluded us from recording demographic variability
and subsequent stratifying the patient group (e.g. age,
gender etc.) and studying factors associated with CHD.
Further, it also prevented us from using combinations
of factors as independent variables. Many other factors
of interest were associated with PS velocity and these
associations must be studied in detail in a larger cohort
with patients stratified by treatment(s), age, gender,
vascular pathology etc. It is apparent that the current
US technology lacks the resolution for estimating L-
CCA velocity profile. However, newer technology is
entering the market that promises to provide direct
measurement of the velocity profile. Lastly it would
have been interesting to study the association between
vascular flow properties and atherogenesis in a longitu-
dinal study.
Conclusion
Ours was a pilot study with two end points; assessing
the feasibility of using a portable US machine to study
blood flow factors in a routine clinical setting and
investigating associations between flow measurements
and CHD. The data from the scans suggest that low-
cost US measurement could principally be a suitable
and capable tool but a greater resolution is required for
assessment of flow for both, ease and accuracy. Radio
frequency data output which is available in more
sophisticated equipment is desirable due to the advan-
tages of ease of data processing. It is interesting that
mean PS velocity differed between the patient groups.
We would in the future like to further investigate the
mean PS velocity as a prognostic marker in blood ves-
sels varying in diameter (including adjustment for med-
ication and severity of atheroma in patients using
angiogram results etc) for atherosclerosis. Thus, PS
velocity which is a robust easily measured factor may
be important as a non-invasive real time marker of
atherogenesis that could have major clinical use.
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